Javier Saez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1187458/publications.pdf

Version: 2024-02-01

86	3,002	28 h-index	51
papers	citations		g-index
88	88	88	3888
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
2	Revisiting the role of acetylcholinesterase in Alzheimerâ \in TM s disease: cross-talk with P-tau and \hat{I}^2 -amyloid. Frontiers in Molecular Neuroscience, 2011, 4, 22.	2.9	208
3	Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5573-5578.	7.1	196
4	Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. Hepatology, 2006, 43, 1257-1266.	7.3	147
5	The Amyloid βâ€Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells. Journal of Neurochemistry, 1997, 69, 1177-1184.	3.9	112
6	Molecular Isoform Distribution and Glycosylation of Acetylcholinesterase Are Altered in Brain and Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Neurochemistry, 1999, 72, 1600-1608.	3.9	99
7	Altered Levels of Acetylcholinesterase in Alzheimer Plasma. PLoS ONE, 2010, 5, e8701.	2.5	93
8	Acetylcholinesterase Is Increased in the Brains of Transgenic Mice Expressing the Câ€Terminal Fragment (CT100) of the βâ€Amyloid Protein Precursor of Alzheimer's Disease. Journal of Neurochemistry, 1998, 71, 723-731.	3.9	92
9	Brain cholinergic impairment in liver failure. Brain, 2008, 131, 2946-2956.	7.6	88
10	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 132-136.	2.9	69
11	Nogo-A Expression in the Human Hippocampus in Normal Aging and in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 433-444.	1.7	62
12	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. Journal of Neuroscience Research, 2003, 72, 520-526.	2.9	55
13	\hat{l}^2 -amyloid controls altered Reelin expression and processing in Alzheimer's disease. Neurobiology of Disease, 2010, 37, 682-691.	4.4	53
14	Neuromuscular Junction Impairment in Amyotrophic Lateral Sclerosis: Reassessing the Role of Acetylcholinesterase. Frontiers in Molecular Neuroscience, 2016, 9, 160.	2.9	49
15	Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. Journal of Neuroscience Research, 1993, 35, 678-689.	2.9	45
16	The β-amyloid peptide compromises Reelin signaling in Alzheimer's disease. Scientific Reports, 2016, 6, 31646.	3.3	44
17	Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. Journal of Neurochemistry, 2002, 81, 441-448.	3.9	41
18	Beta-Amyloid Impairs Reelin Signaling. PLoS ONE, 2013, 8, e72297.	2.5	40

#	Article	IF	CITATIONS
19	Wheat germ agglutininâ€binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. Journal of Neurochemistry, 2001, 79, 1022-1026.	3.9	39
20	Levels of ADAM10 are reduced in Alzheimer's disease CSF. Journal of Neuroinflammation, 2018, 15, 213.	7.2	39
21	Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet, The, 1997, 350, 929.	13.7	38
22	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. Hepatology, 2006, 43, 444-453.	7.3	38
23	Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 664-667.	1.9	36
24	Glutamate-induced activation of nitric oxide synthase is impaired in cerebral cortexinÂvivoin rats with chronic liver failure. Journal of Neurochemistry, 2007, 102, 51-64.	3.9	35
25	Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. Journal of Neurochemistry, 2006, 96, 97-104.	3.9	34
26	Caspase-3 activation by \hat{l}^2 -amyloid and prion protein peptides is independent from their neurotoxic effect. Neuroscience Letters, 2000, 293, 207-210.	2.1	31
27	Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid β-peptide. Neuroscience Letters, 2002, 325, 199-202.	2.1	31
28	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
29	Reelin in Alzheimer's Disease, Increased Levels but Impaired Signaling: When More is Less. Journal of Alzheimer's Disease, 2016, 52, 403-416.	2.6	30
30	ApoER2 processing by presenilinâ€1 modulates reelin expression. FASEB Journal, 2014, 28, 1543-1554.	0.5	29
31	Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer?s disease. Journal of Neurochemistry, 2007, 101, 1701-1711.	3.9	28
32	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	3.3	28
33	Reelin is overexpressed in the liver and plasma of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with cirrhosis. International Journal of Biochemistry and Cell Biology, 2008, 40, 766-775.	2.8	27
34	Presenilin 1 Interacts with Acetylcholinesterase and Alters Its Enzymatic Activity and Glycosylation. Molecular and Cellular Biology, 2008, 28, 2908-2919.	2.3	26
35	Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2016, 53, 831-841.	2.6	26
36	Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with $\hat{1}^2$ -amyloid peptides. Brain Research, 2003, 965, 283-286.	2.2	25

#	Article	IF	CITATIONS
37	Association between acetylcholinesterase and \hat{l}^2 -amyloid peptide in Alzheimer's cerebrospinal fluid. Chemico-Biological Interactions, 2008, 175, 209-215.	4.0	25
38	Readthrough Acetylcholinesterase Is Increased in Human Liver Cirrhosis. PLoS ONE, 2012, 7, e44598.	2.5	25
39	Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiology of Aging, 2012, 33, 624.e23-624.e34.	3.1	24
40	Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 96.	6.2	24
41	Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. Neurobiology of Aging, 2012, 33, 627.e27-627.e37.	3.1	23
42	Decreased generation of Câ€terminal fragments of ApoER2 and increased reelin expression in Alzheimer's disease. FASEB Journal, 2018, 32, 3536-3546.	0.5	23
43	Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1317, 210-218.	3.8	22
44	Bile duct ligation plus hyperammonemia in rats reproduces the alterations in the modulation of soluble guanylate cyclase by nitric oxide in brain of cirrhotic patients. Neuroscience, 2005, 130, 435-443.	2.3	22
45	CSF Presenilin-1 complexes are increased in Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 46.	5.2	22
46	Acetylcholinesterase Modulates Presenilin-1 Levels and \hat{I}^3 -Secretase Activity. Journal of Alzheimer's Disease, 2014, 41, 911-924.	2.6	22
47	Heteromers of amyloid precursor protein in cerebrospinal fluid. Molecular Neurodegeneration, 2015, 10, 2.	10.8	22
48	Ricinus communis agglutinin I reacting and non-reacting butyrylcholinesterase in human cerebrospinal fluid. Neuroscience Letters, 1992, 145, 59-62.	2.1	20
49	Molecular forms of acetyl- and butyrylcholinesterase in human glioma. Neuroscience Letters, 1996, 206, 173-176.	2.1	20
50	Acetylcholinesterase Protein Level Is Preserved in the Alzheimer's Brain. Journal of Molecular Neuroscience, 2014, 53, 446-453.	2.3	20
51	An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease. Acta Neurologica Scandinavica, 2000, 102, 49-52.	2.1	19
52	Inhibition of \hat{I}^3 -Secretase Leads to an Increase in Presenilin-1. Molecular Neurobiology, 2018, 55, 5047-5058.	4.0	19
53	Plasma ACE2 species are differentially altered in COVIDâ€19 patients. FASEB Journal, 2021, 35, e21745.	0.5	18
54	Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in alzheimer's disease. Brain Research, 2001, 889, 247-250.	2.2	17

#	Article	IF	CITATIONS
55	Tau phosphorylation by glycogen synthase kinase $3\hat{l}^2$ modulates enzyme acetylcholinesterase expression. Journal of Neurochemistry, 2021, 157, 2091-2105.	3.9	17
56	Monomers and dimers of acetylcholinesterase in human meningioma are anchored to the membrane by glycosylphosphatidylinositol. Neuroscience Letters, 1995, 195, 101-104.	2.1	16
57	Acetylcholinesterase activity and molecular isoform distribution are altered after focal cerebral ischemia. Molecular Brain Research, 2003, 117, 240-244.	2.3	15
58	Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimerââ,¬â"¢s Disease. Frontiers in Neurology, 2015, 6, 125.	2.4	15
59	Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma. Neuroscience, 2001, 107, 199-208.	2.3	14
60	Altered Glycosylation of Acetylcholinesterase in the Creutzfeldt-Jakob Cerebrospinal Fluid. Journal of Molecular Neuroscience, 2006, 30, 65-66.	2.3	14
61	Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease. Journal of Alzheimer's Disease, 2001, 3, 323-328.	2.6	13
62	Acetylcholinesterase activation in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. Neuroscience Letters, 2003, 348, 123-125.	2.1	13
63	HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain. Molecular Neurobiology, 2017, 54, 188-199.	4.0	13
64	α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 139.	6.2	13
65	Identification of a 31-bp Deletion in the RELN Gene Causing Lissencephaly with Cerebellar Hypoplasia in Sheep. PLoS ONE, 2013, 8, e81072.	2.5	12
66	Measurement of CSF αâ€synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease. Journal of Neurochemistry, 2019, 150, 218-230.	3.9	12
67	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	4.4	11
68	Characterization of molecular forms of acetyl- and butyrylcholinesterase in human acoustic neurinomas. Neuroscience Letters, 1999, 274, 56-60.	2.1	10
69	Quantification of the Transcripts Encoding Different Forms of AChE in Various Cell Types: Real-Time PCR Coupled with Standards in Revealing the Copy Number. Journal of Molecular Neuroscience, 2014, 53, 461-468.	2.3	9
70	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. Neurobiology of Aging, 2014, 35, 1526-1536.	3.1	9
71	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. Molecular Neurodegeneration, 2016, 11, 66.	10.8	9
72	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	1.1	9

#	Article	IF	CITATIONS
73	The apolipoprotein receptor LRP3 compromises APP levels. Alzheimer's Research and Therapy, 2021, 13, 181.	6.2	9
74	Elevated Plasma Reelin Levels in Children With Autism. Frontiers in Psychiatry, 2020, 11, 242.	2.6	8
75	Inhibition of neurite outgrowth from chick sympathetic neurons by cholinesterase inhibitors is not mediated by binding to cholinesterases. Neuroscience Letters, 1999, 266, 77-80.	2.1	7
76	Acetylcholinesterase level and molecular isoforms are altered in brain of Reelin Orleans mutant mice. Journal of Neurochemistry, 2003, 87, 773-779.	3.9	5
77	Intraperitoneal administration of 340kDa human plasma butyrylcholinesterase increases the level of the enzyme in the cerebrospinal fluid of rats. Neuroscience Letters, 2005, 383, 93-98.	2.1	4
78	Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2017, 57, 1281-1291.	2.6	4
79	Characterization of Cerebrospinal Fluid BACE1 Species. Molecular Neurobiology, 2019, 56, 8603-8616.	4.0	4
80	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. Clinica Chimica Acta, 2019, 490, 6-11.	1.1	3
81	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients. International Journal of Molecular Sciences, 2022, 23, 7522.	4.1	3
82	Alzheimer's Disease and Reelin. , 2008, , 401-409.		1
83	P3-384 Decreased level and altered glycosylation of acetylcholinesterase in creutzfeld-jakob lumbar cerebrospinal fluid. Neurobiology of Aging, 2004, 25, S464-S465.	3.1	0
84	P2-115: CEREBROSPINAL FLUID PRESENILIN-1 COMPLEXES: A POTENTIAL BIOMARKER FOR ALZHEIMER'S DISEASE., 2014, 10, P513-P513.		0
85	P3-037: THE B-AMYLOID PEPTIDE COMPROMISES REELIN SIGNALING IN ALZHEIMER'S DISEASE. , 2014, 10, P641-P641.		0
86	Expression and Glycosylation of Acetylcholinesterase in Alzheimer's Disease Brain. , 1998, , 175-179.		0